Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.42 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.41 |
| ▸ | ITGAL | P20701 | 1/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CRHBP | P24387 | 2/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | USP1 | O94782 | 2/20 | 0.34 |
| ▸ | XIAP | P98170 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12609018 | 1.00 | MAP3K14 (0.42) | MAP3K14ITGB2ICAM1ITGALSSTR4 | |
| SCHEMBL12609033 | 1.00 | MAP3K14 (0.42) | MAP3K14ITGB2ICAM1ITGALSSTR4 | |
| SCHEMBL14313741 | 0.89 | ITGB2 (0.39) | MAP3K14ITGB2ICAM1ITGALSSTR4 | |
| SCHEMBL17084099 | 0.89 | ITGB2 (0.39) | MAP3K14ITGB2ICAM1ITGALSSTR4 | |
| SCHEMBL29332749 | 0.86 | MAP3K14 (0.40) | MAP3K14ITGB2ICAM1ITGALSSTR4 | |
| SCHEMBL21423461 | 0.86 | ITGB2 (0.39) | MAP3K14ITGB2ICAM1ITGALSSTR4 | |
| SCHEMBL28297416 | 0.81 | ITGB2 (0.41) | MAP3K14ITGB2ICAM1ITGALSSTR4 | |
| SCHEMBL13139753 | 0.81 | LTB4R (0.40) | LMNASMN1; SMN2 | |
| SCHEMBL13059129 | 0.81 | LTB4R (0.40) | LMNASMN1; SMN2 | |
| SCHEMBL20077675 | 0.81 | LTB4R (0.40) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
| WO-2023129564-A9 | DEGRADERS OF GRK2 AND USES THEREOF | CYGNAL THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11827617-B2 | Piperidinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230373950-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373950-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230355622-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355622-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080214580-A1 | 6-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE AND PURINONE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080085898-A1 | 8-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080051404-A1 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070066666-A1 | Thiazole compounds | SMITHKLINE BEECHAM CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070060576-A1 | Process for preparing benzimidazole thiophenes | SMITHKLINE BEECHAM CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20070060576-A1 | Process for preparing benzimidazole thiophenes | SMITHKLINE BEECHAM CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20070003680-A1 | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers | SENOMYX, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827617-B2 | Piperidinyl nociceptin receptor compounds | OPRL1, OPRK1, OPRM1 | MAP3K14 1645/4885ITGB2 2040/4885ICAM1 1035/4885 |
| US-20080085898-A1 | 8-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | TPMT, KIT, ADORA2A | MAP3K14 3159/4885ITGB2 3104/4885ICAM1 974/4885 |
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | BCL2, BCL2L2, BCL2L1 | MAP3K14 2860/4885ITGB2 2633/4885ICAM1 3516/4885 |
| US-20230373950-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | IKZF2, IKZF1, IKZF3 | MAP3K14 2392/4885ITGB2 4446/4885ICAM1 2775/4885 |
| US-20080051404-A1 | Heteroaryl compounds useful as inhibitors of E1 activating enzymes | RCE1, ECE1, UBE2E1 | MAP3K14 1310/4885ITGB2 4243/4885ICAM1 2759/4885 |
| US-20070060576-A1 | Process for preparing benzimidazole thiophenes | CYP3A4, TPMT, TYMP | MAP3K14 2086/4885ITGB2 3714/4885ICAM1 4728/4885 |
| US-20070066666-A1 | Thiazole compounds | CYP3A5, CYP2C19, CYP3A7 | MAP3K14 3717/4885ITGB2 2167/4885ICAM1 4528/4885 |
| US-20080214580-A1 | 6-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE AND PURINONE DERIVATIVES FOR IMMUNOSUPPRESSION | P2RY6, P2RY1, P2RX6 | MAP3K14 2505/4885ITGB2 3654/4885ICAM1 1484/4885 |
| US-20230355622-A1 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | CTSL, PRCP, CPB1 | MAP3K14 2093/4885ITGB2 1989/4885ICAM1 1983/4885 |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | ITGA2B, ITGB6, ITGB1 | MAP3K14 2814/4885ITGB2 9/4885ICAM1 119/4885 |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | CYP3A4, CYP2C19, CYP2B6 | MAP3K14 1473/4885ITGB2 3217/4885ICAM1 4802/4885 |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | MAP3K14 1108/4885ITGB2 4222/4885ICAM1 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.